TAI · 6446.TW
PharmaEssentia Corporation
NT$1,190.00-NT$50.00 (-4.03%)
PharmaEssentia Corporation’s quoted price sits in the upper half of its reported 52-week range, 27.66% below the high.
Loading market information…
TWO · 6547.TWO · TWD
Stock price, earnings
Quote as of Oct 30, 2026, 05:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
Medigen Vaccine Biologics Corp.’s quoted price sits in the lower half of its reported 52-week range, 32.34% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Medigen Vaccine Biologics Corp.’s next earnings report is currently expected on Nov 18, 2026, with estimated earnings per share of NT$0.12. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Medigen Vaccine Biologics Corp.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Medigen Vaccine Biologics Corporation, a biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan. It develops enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; and Quadrivalent influenza vaccine, which is in Phase III clinical trial for the treatment of influenza viruses. The company also develops dengue vaccines, which has completed Phase II clinical trial to treat dengue; anti respiratory syncytial virus (RSV), which is in Phase I clinical trial for the prevention of RSV infection; and COVID-19 vaccine, which is in Phase III clinical trial to prevent COVID-19. The company was incorporated in 2012 and is headquartered in Zhubei, Taiwan. Medigen Vaccine Biologics Corporation operates as a subsidiary of Medigen Biotechnology Corp.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:34 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| NT$144.87M-22.53% vs estimate |
| Q1 2025 | May 9, 2025 | -NT$0.06-175.0% vs estimate | NT$115.43M+0.37% vs estimate |
|---|
| Q4 2024 | Mar 5, 2025 | -NT$0.07-600.0% vs estimate | NT$129.00M-27.53% vs estimate |
|---|
| Q3 2024 | Nov 4, 2024 | NT$0.00+101.44% vs estimate | NT$243.00M+257.35% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$1,190.00-NT$50.00 (-4.03%)
PharmaEssentia Corporation’s quoted price sits in the upper half of its reported 52-week range, 27.66% below the high.
NT$159.00-NT$2.50 (-1.55%)
Lin BioScience, Inc.’s quoted price sits in the upper half of its reported 52-week range, 23.19% below the high.
NT$39.05-NT$1.75 (-4.29%)
Pell Bio-Med Technology Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 97.38% below the high.
NT$379.00-NT$13.00 (-3.32%)
Bora Pharmaceuticals Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 41.78% below the high.
NT$57.40-NT$2.60 (-4.33%)
TaiMed Biologics Inc.’s quoted price sits in the lower half of its reported 52-week range, 23.87% below the high.
NT$17.20-NT$0.30 (-1.71%)
Adimmune Corporation’s quoted price sits in the lower half of its reported 52-week range, 23.56% below the high.
NT$23.00-NT$1.05 (-4.37%)
Advagene Biopharma Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 36.38% below the high.
NT$14.90-NT$0.40 (-2.61%)
Enimmune corporation’s quoted price sits in the lower half of its reported 52-week range, 33.92% below the high.
